







Lab No. : BLG/25-02-2023/SR7338023

Patient Name : SUBIR KR DAS Age : 36 Y 8 M 15 D

Gender : M

Lab Add. : Newtown, Kolkata-700156

Ref Dr. : Dr.MEDICAL OFFICER
Collection Date: 25/Feb/2023 08:55AM

Report Date : 25/Feb/2023 01:03PM



Test Name	Result	Unit	Bio Ref. Interval	Method
BILIRUBIN (DIRECT), GEL SERUM				
BILIRUBIN (DIRECT)	0.10	mg/dL	<0.2 mg/dL	Vanadate oxidation
SGOT/AST, GEL SERUM				
SGOT/AST	18.00	U/L	13-40 U/L	Modified IFCC
PHOSPHORUS-INORGANIC, BLOOD, GEL	. SERUM			
PHOSPHORUS-INORGANIC,BLOOD	3.3	mg/dL	2.4-5.1 mg/dL	Phosphomolybdate/UV
URIC ACID, BLOOD , GEL SERUM				
URIC ACID,BLOOD	6.30	mg/dL	3.5-7.2 mg/dL	Uricase/Peroxidase
THYROID PANEL (T3, T4, TSH), GEL SER	UM			
T3-TOTAL (TRI IODOTHYRONINE)	1.10	ng/ml	0.60-1.81 ng/ml	CLIA
T4-TOTAL (THYROXINE)	10.0	μg/dL	3.2-12.6 μg/dL	CLIA
TSH (THYROID STIMULATING HORMONE)	3.29	μIU/mL	0.55-4.78 μIU/mL	CLIA

Serum TSH levels exhibit a diurnal variation with the peak occurring during the night and the nadir, which approximates to 50% of the peak value, occurring between 1000 and 1600 hours.[1,2]

References:

- 1. Bugalho MJ, Domingues RS, Pinto AC, Garrao A, Catarino AL, Ferreira T, Limbert E and Sobrinho L. Detection of thyroglobulin mRNA transcripts in peripheral blood of *individuals with and without thyroid glands: evidence for thyroglobulin expression by blood cells. Eur J Endocrinol* 2001:145:409-13.
- 2. Bellantone R, Lombardi CP, Bossola M, Ferrante A,Princi P, Boscherini M et al. Validity of thyroglobulin mRNA assay in peripheral blood of postoperative thyroid carcinoma patients in predicting tumor recurrence varies according to the histologic type: results of a prospective study. Cancer 2001;92:2273-9.

BIOLOGICAL REFERENCE INTERVAL: [ONLY FOR PREGNANT MOTHERS]

Trimester specific TSH LEVELS during pregnancy:

FIRST TRIMESTER: $0.10-3.00~\mu$ IU/mL SECOND TRIMESTER: 0.20 -3.50 μ IU/mL THIRD TRIMESTER: 0.30 -3.50 μ IU/mL

References:

- 1. Erik K. Alexander, Elizabeth N. Pearce, Gregory A. Brent, Rosalind S. Brown, Herbert Chen, Chrysoula Dosiou, William A. Grobman, Peter Laurberg, John H. Lazarus, Susan J. Mandel, Robin P. Peeters, and Scott Sullivan. Thyroid. Mar 2017.315-389. http://doi.org/10.1089/thy.2016.0457
- 2. Kalra S, Agarwal S, Aggarwal R, Ranabir S. Trimester-specific thyroid-stimulating hormone: An indian perspective. Indian J Endocr Metab 2018;22:1-4.









Lab No. : SR7338023	Name : SUBIR KR DAS		Age/G: 36 Y 8 M 15 D / M	Date : 25-02-2023
UREA,BLOOD , GEL SERUN	23.5	mg/dL	19-49 mg/dL	Urease with GLDH
BILIRUBIN (TOTAL), GEL	SERUM			
BILIRUBIN (TOTAL)	0.50	mg/dL	0.3-1.2 mg/dL	Vanadate oxidation
GLUCOSE, FASTING, BLOG	OD, NAF PLASMA			
GLUCOSE,FASTING	87	mg/dL	Impaired Fasting-100-125 .~Diabetes- >= 126.~Fasting is defined as no caloric intake for least 8 hours.	

In the absence of unequivocal hyperglycemia, diagnosis requires two abnormal test results from the same sample or in two separate test samples.

Reference : ADA Standards of Medical Care in Diabetes – 2020. Diabetes Care Volume 43, Supplement 1.

ALKALINE PHOSPHATASE 64.00 U/L 46-116 U/L IFCC standardization **SGPT/ALT**, GEL SERUM SGPT/ALT 29.00 U/L 7-40 U/L Modified IFCC **CREATININE, BLOOD** mg/dL 0.7-1.3 mg/dL Jaffe, alkaline picrate, kinetic 0.80

Dr NEEPA CHOWDHURY MBBS MD (Biochemistry) **Consultant Biochemist**









Lab No. : SR7338023	Name: SUBIR KR DAS		Age/G: 36 Y 8 M 15 D / M	Date: 25-02-2023
SODIUM, BLOOD , GEL SE	ERUM			
SODIUM,BLOOD	140.00	mEq/L	132 - 146 mEq/L	ISE INDIRECT
*CHLORIDE, BLOOD, .				
CHLORIDE,BLOOD	104.00	mEq/L	99-109 mEq/L	ISE INDIRECT
GLUCOSE, PP , BLOOD, N.	AF PLASMA			
GLUCOSE,PP	102	mg/dL	Impaired Glucose Tolerance-140 to 199. Diabetes>= 200.) Gluc Oxidase Trinder

The test should be performed as described by the WHO, using a glucose load containing the equivalent of 75-g anhydrous glucose dissolved in water. In the absence of unequivocal hyperglycemia, diagnosis requires two abnormal test results from the same sample or in two separate test samples.

Reference

ADA Standards of Medical Care in Diabetes – 2020. Diabetes Care Volume 43, Supplement 1.

CALCIUM, BLOOD

CALCIUM,BLOOD 9.60 mg/dL 8.7-10.4 mg/dL Arsenazo III

POTASSIUM, BLOOD, GEL SERUM

POTASSIUM,BLOOD 4.40 mEq/L 3.5-5.5 mEq/L ISE INDIRECT

Dr. SUPARBA CHAKRABARTI MBBS, MD(BIOCHEMISTRY) Consultant Biochemist

Page 3 of 12









Lab No.: SR7338023 Name: SUBIR KR DAS Age/G: 36 Y 8 M 15 D / M Date: 25-02-2023

URINE ROUTINE ALL, ALL, URINE

PHYSI CAL EXAMINATION

COLOUR PALE YELLOW
APPEARANCE SLIGHTLY HAZY

CHEMI CAL EXAMINATION

pH	6.0	4.6 - 8.0	Dipstick (triple indicator method)
SPECIFIC GRAVITY	1.005	1.005 - 1.030	Dipstick (ion concentration method)
PROTEIN	NOT DETECTED	NOT DETECTED	Dipstick (protein error of pH indicators)/Manual
GLUCOSE	NOT DETECTED	NOT DETECTED	Dipstick(glucose-oxidase-peroxidase method)/Manual
KETONES (ACETOACETIC ACID, ACETONE)	NOT DETECTED	NOT DETECTED	Dipstick (Legals test)/Manual
BLOOD	NOT DETECTED	NOT DETECTED	Dipstick (pseudoperoxidase reaction)
BILIRUBIN	NEGATIVE	NEGATIVE	Dipstick (azo-diazo reaction)/Manual
UROBILINOGEN	NEGATIVE	NEGATIVE	Dipstick (diazonium ion reaction)/Manual
NITRITE	NEGATIVE	NEGATIVE	Dipstick (Griess test)
LEUCOCYTE ESTERASE	NEGATIVE	NEGATIVE	Dipstick (ester hydrolysis reaction)

MI CROSCOPI C EXAMINATION

LEUKOCYTES (PUS CELLS) 0-1 /hpf 0-5 Micr	
EPITHELIAL CELLS 0-1 /hpf 0-5 Micro	croscopy
RED BLOOD CELLS NOT DETECTED /hpf 0-2 Micr	croscopy
CAST NOT DETECTED NOT DETECTED Micro	croscopy
CRYSTALS NOT DETECTED NOT DETECTED Micr	croscopy
BACTERIA NOT DETECTED NOT DETECTED Micro	croscopy
YEAST NOT DETECTED NOT DETECTED Micro	croscopy

Note

- 1. All urine samples are checked for adequacy and suitability before examination.
- 2. Analysis by urine analyzer of dipstick is based on reflectance photometry principle. Abnormal results of chemical examinations are confirmed by manual methods.
- 3. The first voided morning clean-catch midstream urine sample is the specimen of choice for chemical and microscopic analysis.
- 4. Negative nitrite test does not exclude urinary tract infections.
- 5. Trace proteinuria can be seen in many physiological conditions like exercise, pregnancy, prolonged recumbency etc.
- 6. False positive results for glucose, protein, nitrite, urobilinogen, bilirubin can occur due to use of certain drugs, therapeutic dyes, ascorbic acid, cleaning agents used in urine collection container.
- 7. Discrepancy between results of leukocyte esterase and blood obtained by chemical methods with corresponding pus cell and red blood cell count by microscopy can occur due to cell lysis.
- 8. Contamination from perineum and vaginal discharge should be avoided during collection, which may falsely elevate epithelial cell count and show presence of bacteria and/or yeast in the urine.

CBC WITH PLATELET & RETICULOCYTE COUNT, EDTA WHOLE BLOOD

HEMOGLOBIN	14.1	g/uL	13 - 17	PHOTOMETRIC
WBC	5.1	*10^3/µL	4 - 10	DC detection method
RBC	5.60	*10^6/µL	4.5 - 5.5	DC detection method
PLATELET (THROMBOCYTE) COUNT	159	*10^3/µL	150 - 450*10^3/μL	DC detection method/Microscopy
DI FFERENTI AL COUNT				
NEUTROPHILS	53	%	40 - 80 %	Flowcytometry/Microscopy
LYMPHOCYTES	33	%	20 - 40 %	Flowcytometry/Microscopy
MONOCYTES	06	%	2 - 10 %	Flowcytometry/Microscopy
EOSINOPHILS	08	%	1-6%	Flowcytometry/Microscopy
BASOPHILS	00	%	0-0.9%	Flowcytometry/Microscopy
CBC SUBGROUP 1				

Lab No. : BLG/25-02-2023/SR7338023 Page 4 of 12

13 - 17

PHOTOMETRIC









Lab No. : SR7338023 Na	me : SUBIR KR DAS		Age/G: 36 Y 8 M 15 D / M	Date : 25-02-2023
HEMATOCRIT / PCV	41.1	%	40 - 50 %	Calculated
MCV	73.3	fl	83 - 101 fl	Calculated
MCH	25.2	pg	27 - 32 pg	Calculated
MCHC	34.4	gm/dl	31.5-34.5 gm/dl	Calculated
RDW - RED CELL DISTRIBUTION	ON WIDTH 15.5	%	11.6-14%	Calculated
RETICULOCYTE COUNT- AUTOMATED,BLOOD	1.3	%	0.5-2.5%	Cell Counter/Microscopy

Oto

DR. NEHA GUPTA MD, DNB (Pathology) Consultant Pathologist

Lab No. : BLG/25-02-2023/SR7338023









Lab No.: SR7338023 Name: SUBIR KR DAS Age/G: 36 Y 8 M 15 D / M Date: 25-02-2023

ESR (ERYTHROCYTE SEDIMENTATION RATE), EDTA WHOLE BLOOD

1stHour 0.00 - 20.00 mm/hr Westergren

BLOOD GROUP ABO+RH [GEL METHOD], EDTA WHOLE BLOOD

Gel Card ABO

Gel Card RH **POSITIVE**

TECHNOLOGY USED: GEL METHOD

ADVANTAGES:

- Gel card allows simultaneous forward and reverse grouping.
- Card is scanned and record is preserved for future reference.
- Allows identification of Bombay blood group. Daily quality controls are run allowing accurate monitoring.

Historical records check not performed.

MBBS, MD (PATHOLOGY) CONSULTANT PATHOLOGIST

Page 6 of 12 Lab No. : BLG/25-02-2023/SR7338023









Lab No. : SR7338023	Name: SUBIR KR DAS		Age/G: 36 Y 8 M 15 D / M	Date : 25-02-2023
URIC ACID, URINE, SPOT	URINE			
URIC ACID, SPOT URINE	14.00	mg/dL	37-92 mg/dL	URICASE
LIPID PROFILE, GEL SER	JM			
CHOLESTEROL-TOTAL	150.00	mg/dL	Desirable: < 200 mg/dL Borderline high: 200-239 mg/dL High: > or =240 mg/dL	Enzymatic
TRIGLYCERIDES	73.00	mg/dL	Normal:: < 150, BorderlineHigh::150-199, High:: 200-499, VeryHigh::>500	GPO-Trinder
HDL CHOLESTEROL	40.00	mg/dl	< 40 - Low 40-59- Optimum 60 - High	Elimination/catalase
LDL CHOLESTEROL DIREC	T 96.0	mg/dL	OPTIMAL : <100 mg/dL, Near optimal/ above optimal : 100-129 mg/dL, Borderline high : 130-159 mg/dL High : 160-189 mg/dL, Very high : >=190 mg/dL	Calculated ,,
VLDL	14	mg/dl	< 40 mg/dl	Calculated
CHOL HDL Ratio	3.8		LOW RISK 3.3-4.4 AVERAGE RISK 4.47-7.1 MODERATE RISK 7.1-11.0 HIGH RISK >11.0	Calculated

Reference: National Cholesterol Education Program. Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. May 16 2001;285(19):2486-97.

TOTAL PROTEIN [BLOOD] ALB:GLO RATIO, .

TOTAL PROTEIN	7.30	g/dL	5.7-8.2 g/dL	BIURET METHOD
ALBUMIN	4.7	g/dL	3.2-4.8 g/dL	BCG Dye Binding
GLOBULIN	2.60	g/dl	1.8-3.2 g/dl	Calculated
AG Ratio	1.81		1.0 - 2.5	Calculated

PDF Attached

GLYCATED HAEMOGLOBIN (HBA1C), EDTA WHOLE BLOOD

GLYCATED HEMOGLOBIN (HBA1C)

5.3

***FOR BIOLOGICAL REFERENCE INTERVAL DETAILS, PLEASE REFER TO THE BELOW MENTIONED REMARKS/NOTE WITH ADDITIONAL CLINICAL

ADDITIONAL CLINIC INFORMATION ***

HbA1c (IFCC) 34.0 mmol/mol HPLC

Clinical Information and Laboratory clinical interpretation on Biological Reference Interval:

Analyzer used: Bio-Rad-VARIANT TURBO 2.0

Method: HPLC Cation Exchange

Recommendations for glycemic targets

- Ø Patients should use self-monitoring of blood glucose (SMBG) and HbA1c levels to assess glycemic control.
- Ø The timing and frequency of SMBG should be tailored based on patients' individual treatment, needs, and goals.
- Ø Patients should undergo HbA1c testing at least twice a year if they are meeting treatment goals and have stable glycemic control.
- Ø If a patient changes treatment plans or does not meet his or her glycemic goals, HbA1c testing should be done quarterly.
- \varnothing For most adults who are not pregnant, HbA1c levels should be <7% to help reduce microvascular complications and macrovascular disease . Action suggested >8% as it indicates poor control.

Lab No. : BLG/25-02-2023/SR7338023 Page 7 of 12









Lab No. : SR7338023 Name : SUBIR KR DAS Age/G : 36 Y 8 M 15 D / M Date : 25-02-2023

Ø Some patients may benefit from HbA1c goals that are stringent.

Result alterations in the estimation has been established in many circumstances, such as after acute/ chronic blood loss, for example, after surgery, blood transfusions, hemolytic anemia, or high erythrocyte turnover; vitamin B_{12} / folate deficiency, presence of chronic renal or liver disease; after administration of high-dose vitamin E / C; or erythropoietin treatment.

Reference: Glycated hemoglobin monitoring BMJ 2006; 333;586-8

References:

- 1. Chamberlain JJ, Rhinehart AS, Shaefer CF, et al. Diagnosis and management of diabetes: synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes. Ann Intern Med. Published online 1 March 2016. doi:10.7326/M15-3016.
- 2. Mosca A, Goodall I, Hoshino T, Jeppsson JO, John WG, Little RR, Miedema K, Myers GL, Reinauer H, Sacks DB, Weykamp CW. International Federation of Clinical Chemistry and Laboratory Medicine, IFCC Scientific Division. Global standardization of glycated hemoglobin measurement: the position of the IFCC Working Group. Clin Chem Lab Med. 2007;45(8):1077-1080.

DR. ANANNYA GHOSH MBBS, MD (Biochemistry)

Consultant Biochemist



Lab No. : BLG/25-02-2023/SR7338023

Lab Add. Ref Dr. **Patient Name** : SUBIR KR DAS : Dr.MEDICAL OFFICER

Age : 36 Y 8 M 15 D **Collection Date:**

Gender : M **Report Date** : 25/Feb/2023 04:44PM



E.C.G. REPORT

		LAFB
T WAVE IMPRESSION	:	11 Degree sinus rhythm
QRS WAVE		-46 Degree
AXIS P WAVE		49 Degree
QTC INTERVAL		377 Ms
QT INTERVAL		367 Ms
QRS DURATION		94 Ms
PR INTERVAL		173 Ms
DATA HEART RATE		63 Bpm

Dr Siddhartha Chakrabarty MD (Medicine) Cardiologist

: BLG/25-02-2023/SR7338023 Lab No.



Lab No. : BLG/25-02-2023/SR7338023

Patient Name : SUBIR KR DAS Ref Dr. : Dr.MEDICAL OFFICER

Age : 36 Y 8 M 15 D Collection Date:

Gender: M **Report Date**: 25/Feb/2023 11:44AM



X-RAY REPORT OF CHEST (PA)

Lab Add.

FINDINGS:

No active lung parenchymal lesion is seen.

Both the hila are normal in size, density and position.

Mediastinum is in central position. Trachea is in midline.

Domes of diaphragm are smoothly outlined. Position is within normal limits.

Lateral costo-phrenic angles are clear.

The cardio-thoracic ratio is normal.

Bony thorax reveals no definite abnormality.

IMPRESSION:

Normal study.

DR. SHUSOVAN SARDAR
MD Radiodiagnosis (AIIMS)

Reg No. 79136(WBMC)

Lab No. : BLG/25-02-2023/SR7338023 Page 10 of 12



Patient Name : SUBIR KR DAS Ref Dr. : Dr.MEDICAL OFFICER

Age : 36 Y 8 M 15 D Collection Date:

Gender: M **Report Date**: 25/Feb/2023 12:49PM



DEPARTMENT OF ULTRASONOGRAPHY REPORT ON EXAMINATION OF WHOLE ABDOMEN

LIVER

Liver is normal (14.70 cm) in size with smooth margins. Parenchymal echotexture of both lobes are normal. No focal mass lesion is seen in liver. Intrahepatic biliary radicals are not dilated. Portal vein branches and hepatic veins are normal.

PORTA

Portal vein is normal in caliber. Common bile duct is not dilated. No intraluminal calculus or soft tissue is seen in CBD.

GALL BLADDER

Gall bladder is normal in size, shape. No intraluminal calculus or mass is seen. Gall bladder wall is normal in thickness. No pericholecystic fluid collection noted.

PANCREAS

Pancreas is normal in size, shape and contour. Parenchymal echogenicity is normal and homogeneous. No focal mass or calcification seen. Main pancreatic duct is not dilated. No peripancreatic fluid collection or pseudocyst noted.

SPLEEN

Spleen is normal in size (9.93 cm), shape, position. Echotexture is normal. No focal lesion is noted. Splenic vein at splenic hilum is normal in caliber. No collateral seen.

KIDNEYS

Both the kidneys are normal in size (Right kidney measures :11.85 x 4.70 cm. and Left kidney measures : 10.70 x 5.85 cm.), shape and position. Surfaces are smooth. Cortical echogenicity and cortical thickness of both kidneys are normal. Normal cortico-medullary differentiation is maintained. No calculus, mass or hydronephrosis is seen in either kidney.

<u>URETER</u>

Ureters are not dilated.

URINARY BLADDER

Urinary bladder is distended, wall thickness appeared normal. No intraluminal pathology (calculi/mass) could be detected.

PROSTATE

Prostate is normal in size. Echotexture appears within normal limits. No focal alteration of its echogenicity is seen

It measures : 2.92 cm. x 2.46 cm. x 2.80 cm.

Lab No. : BLG/25-02-2023/SR7338023



Lab No. : BLG/25-02-2023/SR7338023

Patient Name : SUBIR KR DAS

Age : 36 Y 8 M 15 D

Gender : M

Report Date : 25/Feb/2023 12:49PM

: Dr.MEDICAL OFFICER



Approximate weight = 10.5 gms.

RETROPERITONEUM & PERITONEUM

The aorta and IVC are normal. No enlarged lymph nodes are noted in the retroperitoneum. No free fluid is seen in peritoneum.

Lab Add.

Collection Date:

Ref Dr.

IMPRESSION: Normal study.

Kindly note

- Ø Ultrasound is not the modality of choice to rule out subtle bowel lesion.
- Ø Please Intimate us for any typing mistakes and send the report for correction within 7 days.
- Ø The science of Radiological diagnosis is based on the interpretation of various shadows produced by both the normal and abnormal tissues and are not always conclusive. Further biochemical and radiological investigation & clinical correlation is required to enable the clinician to reach the final diagnosis.

The report and films are not valid for medico-legal purpose. Patient I dentity not verified.

> DR. SHUSOVAN SARDAR MD Radiodiagnosis (AIIMS)

Reg No. 79136(WBMC)

Lab No. BLG/25-02-2023/SR7338023 Page 12 of 12

SURAKSHA DIAGNOSTIC,RAJARHAT,KOLKATA BIO-RAD VARIANT-II TURBO CDM5.4. SN-16122

PATIENT REPORT V2TURBO_A1c_2.0

Patient Data Analysis Data

Sample ID: C02135061091 Analysis Performed: 25/FEB/2023 13:03:56

 Patient ID:
 SR7338023
 Injection Number:
 3058U

 Name:
 Run Number:
 63

 Physician:
 Rack ID:
 0006

 Sex:
 Tube Number:
 6

DOB: Report Generated: 25/FEB/2023 13:14:25

Operator ID: anup

Comments:

	NGSP		Retention	Peak
Peak Name	%	Area %	Time (min)	Area
Unknown		0.2	0.113	2425
A1a		0.7	0.161	10352
A1b		1.7	0.221	25964
LA1c		1.7	0.400	25488
A1c	5.3		0.506	64340
P3		3.3	0.785	50338
P4		1.2	0.868	18736
Ao		86.9	0.999	1310189

Total Area: 1,507,831

HbA1c (NGSP) = 5.3 % HbA1c (IFCC) = 34 mmol/mol

